CRISPR Therapeutics signed a global cross-consent and invention management agreement with Intellia Therapeutics Inc., Caribou Biosciences and ERS Genomics for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

Under the agreement, the parties will maintain and coordinate the prosecution, defense and enforcement of the shared CRISPR/Cas9 foundational patent portfolio worldwide. Additionally, co-owners of the intellectual property will allow cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.

Other parties to the agreement include intellectual property co-owners Regents of the University of California, Emmanuelle Charpentier and the University of Vienna.